
Trump states he does not intend to use medical cannabis, but acknowledges that the substance can be an alternative to opioids and necessary for many patients

Despite the executive order signed by Donald Trump, cannabis continues without federal legalization in the US, keeping the market dependent on state laws

Moving from Schedule I to Schedule III could unlock research, ease tax hurdles, and impact state markets


U.S. President says he is considering the reclassification of cannabis, a measure that could impact research, the market, and federal cannabis policy

Analysis indicates that Donald Trump is considering measures to ease federal rules, including possible cannabis reclassification

Experts analyze the scenario and highlight that the measure meets Anvisa's expectations for the Brazilian market; Analysis reveals that the new legislation does not represent prohibition, but rather a restructuring of the sector focusing on taxation and pharmaceutical control

New legislation redefines hemp and prohibits most broad-spectrum CBD products starting in 2026

Proposal redefining limits and banning derivatives with total THC advances in the Senate with White House support

Former president's post about the benefits of CBD derived from hemp for seniors stirred up the cannabis market in the US

Organizations are pressuring President Trump to legalize marijuana in the US, going beyond mere rescheduling and seeking to repair the damages of historical prohibition

The Trump administration is considering reclassifying marijuana as a lower-risk drug, a move that would facilitate research, investments, and tax deductions for the sector

Sean Spicer stated that federal cannabis legalization will not happen under the Trump administration, despite signs of support for specific reforms during the campaign

Financial contributions from major companies in the sector occurred months before the president's executive measure, aiming for a change in federal legislation

Expectation is that the president will issue an executive order transferring the plant to Schedule III; measure would facilitate research and banking access after cannabis reclassification

Amid tensions with Trump, Gustavo Petro suggests drug policy change and cannabis exports

Agency presents new report with no defined timeline, while experts warn that moving to Schedule III would have profound impacts on research and taxation, but not federal legalization

Statement attributed to Donald Trump about changing federal marijuana classification boosts shares of major companies in the sector

Statement attributed to Donald Trump about changing federal classification of marijuana boosts shares of major companies in the sector

IM Cannabis' decision comes after an executive order by Donald Trump that accelerates the reclassification of marijuana in the North American territory